Selvita S.A (SLV) Fair Value & Analysis
Healthcare · PL · Market cap 534M PLN
Fair value as of: Jun 24, 2026
Analysis
Selvita S.A (SLV) currently trades at 30.35 PLN, while our model-based Fair Value estimate is 4.91 PLN — implying the stock looks roughly 83.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services. It also provides antibody discovery, developability, antibody characterization, ant…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Selvita S.A (SLV) undervalued?
What is the fair value of SLV?
What is the quality score of SLV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.